Quarter
Charts

PROTAGONIST THERAPEUTICS, INC.

PTGX

CIK 0001377121 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$7M
↓-95.6% -$163Mvs FY2024 (Q4)
Gross Profit
$7M
↓-95.6% -$163Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
32/100
  • Profitability
    0ROIC -19.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 12.71 (above 1.5 = solid)
  • Leverage
    94D/E 0.12 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.07x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -95.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -985.2% · trend -188.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project PTGX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$15.18
Total enterprise IV
$965M
Diluted shares
0.06B
Terminal PV
$699M (72% of total)
Year-5 FCF
$82M
YearProjected FCFDiscounted PV
+1$61M$55M
+2$65M$54M
+3$71M$53M
+4$76M$52M
+5$82M$51M
Terminal$1.13B$699M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$46M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$668M
everything owned
Total liabilities
$53M
everything owed
Stockholders' equity
$615M
shareholder claim
Net debt
$-119M
Net cash position ($119M)

Recent performance · 45 quarters

Revenue↓-95.6% -$163M
$7M
Net Income↓-18.5% -$6M
$-39M
Free Cash Flow↑+53.5% +$166K
$-144K
Operating Margin↓-98.5pts
-985.2%

Drill down

PTGX Sankey

See PROTAGONIST THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

PTGX Charts

45 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

PTGX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics